Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Aug;12(2):76-78.
doi: 10.17925/EE.2016.12.02.76. Epub 2016 Aug 28.

Lessons From LEADER - All-round Leadership

Sanjay Kalra  1
Affiliations
Editorial

Lessons From LEADER - All-round Leadership

Sanjay Kalra. Eur Endocrinol. 2016 Aug.

Abstract

The large multinational, randomised, double-blind LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation) trial recently reported the cardiovascular (CV) benefits achieved with liraglutide therapy in type 2 diabetes mellitus (T2DM). This editorial analyses the primary and secondary CV outcomes (CVO) results of the LEADER trial, and discusses the impact these will have on clinical practice of diabetes in specific, and medicine in general. It delves into the evolution of clinical and biochemical outcomes used in diabetes, and discusses the role of liraglutide in shaping future outcomes. The editorial describes the potential role of liraglutide in primary, secondary and tertiary prevention of CV disease (CVD), and suggests exaptation of this molecule for use in cardiology, nephrology and neurology.

Keywords: Cardiovascular outcomes; LEADER; diabetes; empagliflozin; liraglutide; lixisenatide; prevention.

PubMed Disclaimer

References

    1. Marso S. P., Daniels G. H., Brown-Frandsen K.. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jun 13; [Epub ahead of print] - PMC - PubMed
    1. Pfeffer M. A., Claggett B., Diaz R.. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57. - PubMed
    1. Zinman B1, Wanner C., Lachin J. M.. et al. EMPA-REG OUTCOME Investigators, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117–28. - PubMed
    1. Kalra S., Jain A., Ved J., Unnikrishnan A. G.. Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect. Indian J Endocr Metab. [Epub ahead of print] - PMC - PubMed
    1. Sattar N., McLaren J., Kristensen S. L.. et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59:1333–9. - PMC - PubMed

Publication types

LinkOut - more resources